---
figid: PMC8870611__cancers-14-01026-g002
figtitle: Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
organisms:
- Fasciola hepatica
- Clonorchis sinensis
- Opisthorchis viverrini
- Homo sapiens
- Rattus norvegicus
- gut metagenome
- Bikinia letestui
- Rat sarcoma virus
- NA
organisms_ner:
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC8870611
filename: cancers-14-01026-g002.jpg
figlink: /pmc/articles/PMC8870611/figure/cancers-14-01026-f002/
number: F2
caption: 'Signaling pathways in cholangiocarcinoma. Multiple signaling pathways are
  involved in the development and progression of CCA. Receptor tyrosine kinases activate
  the RAS-MAPK pathway and the PI3K-AKT pathway. IL-6 induces the JAK/STAT signaling
  pathway. Consequently, these pathways impact important cellular processes, such
  as cell proliferation, differentiation, survival, and angiogenesis. IDH 1/2 mutations
  lead to the accumulation of the oncometabolite intracellular 2-hydroxyglutarate
  (2-HG). Adapted from []. FGFR2: Fibroblast growth factor receptor 2; EGF: Epidermal
  growth factor; EGFR: Epidermal growth factor receptor; Her2/neu: Human epidermal
  growth factor receptor 2; VEGF: Vascular endothelial growth factor; VEGFR: Vascular
  endothelial growth factor receptor; HGF: Hepatocyte growth factor; MET: C-met-encoded
  receptor for hepatocyte growth factor; IL-6: Interleukin-6; JAK: Janus kinase; SOCS3:
  Suppressor of cytokine signaling 3; STAT3: Signal transducer and activator of transcription
  protein; RAS: Rat sarcoma; RAF: Rat fibrosarcoma; MEK1/2: Mitogen-activated protein
  kinase kinase; ERK1/2: Extracellular signal-regulated kinase 1/2; PI3K: Phosphatidylinositol
  3 kinase; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin; α-KG: α-Ketoglutaric
  acid; 2-HG: 2- hydroxyglutarate; IDH: Isocitrate dehydrogenase; TCA cycle: Citric
  acid cycle.'
papertitle: Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.
reftext: Sandra Pavicevic, et al. Cancers (Basel). 2022 Feb;14(4):1026.
year: '2022'
doi: 10.3390/cancers14041026
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: cholangiocarcinoma | biliary tract cancer | biomarker | prognosis | predictive
  | targeted therapy
automl_pathway: 0.9593592
figid_alias: PMC8870611__F2
figtype: Figure
redirect_from: /figures/PMC8870611__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8870611__cancers-14-01026-g002.html
  '@type': Dataset
  description: 'Signaling pathways in cholangiocarcinoma. Multiple signaling pathways
    are involved in the development and progression of CCA. Receptor tyrosine kinases
    activate the RAS-MAPK pathway and the PI3K-AKT pathway. IL-6 induces the JAK/STAT
    signaling pathway. Consequently, these pathways impact important cellular processes,
    such as cell proliferation, differentiation, survival, and angiogenesis. IDH 1/2
    mutations lead to the accumulation of the oncometabolite intracellular 2-hydroxyglutarate
    (2-HG). Adapted from []. FGFR2: Fibroblast growth factor receptor 2; EGF: Epidermal
    growth factor; EGFR: Epidermal growth factor receptor; Her2/neu: Human epidermal
    growth factor receptor 2; VEGF: Vascular endothelial growth factor; VEGFR: Vascular
    endothelial growth factor receptor; HGF: Hepatocyte growth factor; MET: C-met-encoded
    receptor for hepatocyte growth factor; IL-6: Interleukin-6; JAK: Janus kinase;
    SOCS3: Suppressor of cytokine signaling 3; STAT3: Signal transducer and activator
    of transcription protein; RAS: Rat sarcoma; RAF: Rat fibrosarcoma; MEK1/2: Mitogen-activated
    protein kinase kinase; ERK1/2: Extracellular signal-regulated kinase 1/2; PI3K:
    Phosphatidylinositol 3 kinase; AKT: Protein kinase B; mTOR: Mammalian target of
    rapamycin; α-KG: α-Ketoglutaric acid; 2-HG: 2- hydroxyglutarate; IDH: Isocitrate
    dehydrogenase; TCA cycle: Citric acid cycle.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Fgfr2
  - Egf
  - Egfr
  - Map2k1
  - Mapk3
  - Mapk1
  - Erbb2
  - Vegfa
  - Pik3cg
  - Akt1
  - Mtor
  - Hgf
  - Stat3
  - Il6
  - Ccne1
  - Socs3
  - Idh3g
  - FGFR2
  - EGF
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - ERBB2
  - NEU1
  - NEURL1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - KDR
  - FLT1
  - FLT4
  - HGF
  - IL6
  - SOS1
  - STAT3
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOCS3
  - IDH1
  - IDH2
  - htl
  - mi
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - rl
  - Nrt
  - neur
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Tor
  - hop
  - bsk
  - CycE
  - cyc
  - Idh
  - Idh3b
  - fgfr2
  - egf
  - celsr1a
  - egfra
  - rab1ab
  - map2k1
  - map2k2a
  - mapk3
  - her2
  - vegfaa
  - mtor
  - stat3
  - il6
  - socs3a
---
